















# ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE

|  | Preclinical   | Phase I   | Phase II | Phase IIb/III & III | Registration   |
|--|---|---|----------|---------------------|--|
|  Lassa fever                                | University of Oxford  |   | IAVI     |                     |  |
|  MERS                                       | Uvax  | IDT Barinthus/<br>University of Oxford                        |          |                     |  |
|  Nipah                                      |   | PHV University of Oxford                                      |          |                     |  |
|  Rift Valley fever                          | UC Davis Afrigen  | Wageningen U. University of Oxford and KEMRI – Wellcome Trust |          |                     |  |
|  Chikungunya                                |   |   |          | IVI/Bharat          | Valneva  |
|  COVID-19*                                  |   |   |          |                     | SK Bioscience Biological E<br>Moderna Clover<br>Novavax AZ/Oxford<br>University of Hong Kong |
|  Broadly protective Betacoronavirus (BPBC) | MigVax VIDO<br>IVI CPI/CalTech<br>Bharat/U Syd/ExcellGene NEC<br>SK Bioscience Intravacc<br>Panacea/THSTI |   |          |                     |  |

(\*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

|  | Preclinical              |                     | Phase I | Phase II | Phase IIb/III & III | Registration |
|--|--------------------------|---------------------|---------|----------|---------------------|--------------|
| <div>Disease X</div> | Akagera                  | Tiba bio            | Lemonex | BioNTech |                     |              |
|  | Chungbuk University      | Gennova*            |         |          |                     |              |
|  | University of Queensland | Celestial           |         |          |                     |              |
|  | Moderna                  | Emervax             |         |          |                     |              |
|  | SK bio                   | HMRI                |         |          |                     |              |
|  | University of Oxford     | Imperial            |         |          |                     |              |
|  | Curevac                  | Amplitude           |         |          |                     |              |
|  | Boost Biopharma          | Nagasaki University |         |          |                     |              |
|  | Centivax                 | VitriVax            |         |          |                     |              |



(\*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.

| DISEASE   | DEVELOPER                                     | PHASE         | PLATFORM        | CEPI FUNDING (IN USD) |
|---|---|---------------|-----------------|-----------------------|
|  Lassa fever       | University of Oxford                          | Preclinical   | Viral Vector    | Up to \$19 million‡   |
|   | IAVI  | Phase 2       | Viral Vector    | Up to \$64.4 million  |
|  MERS              | University of Oxford + Barinthus              | Phase I       | Viral vector    | Up to \$47 million‡   |
|   | IDT   | Phase I       | Viral vector    | Up to \$36 million    |
|   | Uvax bio                                      | Preclinical   | Nanoparticle    | Up to \$2.6 million   |
|  Nipah             | University of Oxford                          | Phase I       | Viral Vector    | Up to \$19 million‡   |
|   | PHV   | Phase I       | Viral vector    | Up to \$43.6 million  |
|  Rift Valley fever | UC Davis                                      | Preclinical   | Live attenuated | Up to \$40 million    |
|   | Wageningen University                         | Phase I       | Live attenuated | Up to \$38.4 million  |
|   | University of Oxford and KEMRI-Wellcome Trust | Phase I       | Viral Vector    | Up to \$3.7 million   |
|   | Afrigen                                       | Preclinical   | RNA             | Up to \$6.2 million   |
|  Chikungunya       | IVI/Bharat                                    | Phase IIb/III | Inactivated     | Up to \$14.1 million  |
|   | Valneva                                       | Registration  | Live attenuated | Up to \$65.9 million  |
|  COVID-19        | SK Bioscience                                 | Registration  | Protein based   | Up to \$210 million   |
|   | Biological E                                  | Registration  | Protein based   | Up to \$14 million    |
|   | Moderna                                       | Registration  | Protein based   | Up to \$1 million     |
|   | Clover  | Registration  | Protein based   | Up to \$397.4 million |
|   | AZ/University of Oxford                       | Registration  | Viral vector    | Up to \$384 million   |
|   | Novavax                                       | Registration  | Protein based   | Up to \$399 million   |

(‡) Includes Lassa, MERS and Nipah funding

(\*\*) Includes COVID-19 variant and BPBC funding. Project funding complete.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

|   |  |                              |             |               |  |
|---|--|------------------------------|-------------|---------------|--|
|   | Broadly protective Beta-coronavirus (BPBC) | MigVax                       | Preclinical | Protein based | Up to \$4.3 million  |
|   |  | BioNet                       | Preclinical | RNA           | Up to \$16.9 million                                       |
|   |  | VIDO                         | Preclinical | Protein based | Up to \$22 million   |
|   |  | Bharat/ U Sydney/ ExcellGene | Preclinical | Protein based | Up to \$19.9 million                                       |
|   |  | CPI/Caltech                  | Preclinical | Protein based | Up to \$30 million   |
|   |  | NEC                          | Preclinical | RNA           | Up to \$4.8 million  |
|   |  | SK Bioscience                | Preclinical | Protein based | Up to \$50 million   |
|   |  | Panacea/THSTI                | Preclinical | Protein based | Up to \$12.5 million                                       |
|   |  | Intravacc                    | Preclinical | Protein based | Up to \$4.8 million  |
|  | Disease X                                  | Akagera                      | Preclinical | RNA           | Up to \$1.5 million  |
|   |  | Amplitude                    | Preclinical | RNA           | Up to \$1 million  |
|   |  | BioNTech                     | Phase IIa   | RNA           | Up to \$72 million   |
|   |  | Boost Biopharma              | Preclinical | Protein based | Up to \$5 million  |
|   |  | Celestial                    | Preclinical | RNA           | Up to \$0.7 million  |
|   |  | Centivax                     | Preclinical | RNA           | Up to \$5.0 million  |
|   |  | Chungbuk National University | Preclinical | RNA           | Up to \$0.9 million  |
|   |  | Curevac                      | Preclinical | RNA           | Up to \$34 million   |
|   |  | Emervax                      | Preclinical | RNA           | Up to \$2.2 million  |
|   |  | Gennova                      | Preclinical | RNA           | Up to \$16.98 million##                                    |
|   |  | HMRI                         | Preclinical | RNA           | Up to \$3.8 million  |
|   |  | Imperial College London      | Preclinical | RNA           | Up to \$8.4 million  |
|   |  | Lemonex                      | Phase I     | RNA           | Up to \$4.9 million  |
|   |  | Moderna                      | Preclinical | RNA           | Not yet at a stage where CEPI provides funding to Moderna. |
|   |  | Nagasaki University          | Preclinical | RNA           | Up to \$5 million  |
|   |  | University of Oxford         | Preclinical | Viral Vector  | Up to \$80 million   |
|   |  | University of Queensland     | Preclinical | Protein based | Up to \$10.6 million                                       |
|   |  | SK Bioscience                | Preclinical | RNA           | Up to \$40 million   |
|   |  | Tiba Bio                     | Preclinical | RNA           | Up to \$2 million  |
|   |  | VitriVax                     | Preclinical | ALTA®         | Up to \$5 million  |

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.